User:Mr. Ibrahem/Talimogene laherparepvec

Talimogene laherparepvec (T-Vec), sold under the brand name Imlygic, is a medication used to treat melanoma that cannot be operated on. Specifically it is used for melanoma within and just under the skin. It is given by directly injecting into lesions. It has not been shown to affected life expectancy.

Common side effects include tiredness, fever, nausea, and pain at the site of injection. Other side effects include may include herpes infections, cellulitis or skin death at the site of injection, vasculitis, and plamacytoma. Use during pregnancy may harm the baby. It should not be used in people with a severely impaired immune system. It is a genetically engineered herpes virus (an oncolytic virus) which infects and multiplies inside melanoma cells, resulting in their death. It also stimulates an immune response against the cancer.

Talimogene laherparepvec was approved in the United States and Europe in 2015. In the United States it may cost up to 23,000 per dose as of 2021. In the United Kingdom this amount costs the NHS about £6,700.